Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 11/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | KAT7 | O95251 | 1/20 | 0.33 |
| ▸ | KAT6B | Q8WYB5 | 1/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.33 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.33 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29571058 | 1.00 | MAT2A (0.59) | MAT2APIK3CAMAPK7TNK2SCN9A | |
| SCHEMBL29570516 | 0.90 | MAT2A (0.63) | MAT2AMAPK7TNK2 | |
| SCHEMBL22094109 | 0.90 | MAT2A (0.63) | MAT2AMAPK7TNK2 | |
| SCHEMBL22093440 | 0.87 | MAT2A (0.64) | MAT2AMAPK7TNK2SCN9A | |
| SCHEMBL29570934 | 0.87 | MAT2A (0.64) | MAT2AMAPK7TNK2SCN9A | |
| SCHEMBL22093485 | 0.85 | MAT2A (0.80) | MAT2AMAPK7 | |
| SCHEMBL29570537 | 0.85 | MAT2A (0.80) | MAT2AMAPK7 | |
| SCHEMBL22103150 | 0.84 | MAT2A (0.53) | MAT2A | |
| SCHEMBL29569845 | 0.84 | MAT2A (0.53) | MAT2A | |
| SCHEMBL22103376 | 0.82 | MAT2A (0.53) | MAT2APTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130759-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCE, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11084798-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-11084798-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-11046691-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046691-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2020123395-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046691-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | MAT2A 2/4885PIK3CA 694/4885MAPK7 3137/4885 |
| US-11130759-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | MAT2A 2/4885PIK3CA 694/4885MAPK7 3137/4885 |
| US-11084798-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | MAT2A 2/4885PIK3CA 694/4885MAPK7 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.